Insider Selling: Illumina (NASDAQ:ILMN) Director Sells $33,499,400.00 in Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 220,000 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $152.27, for a total transaction of $33,499,400.00. Following the completion of the transaction, the director owned 3,280,048 shares in the company, valued at approximately $499,452,908.96. This trade represents a 6.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Illumina Price Performance

NASDAQ:ILMN opened at $170.93 on Thursday. Illumina, Inc. has a 12 month low of $81.75 and a 12 month high of $172.49. The firm has a market cap of $25.86 billion, a PE ratio of 31.08, a price-to-earnings-growth ratio of 2.69 and a beta of 1.50. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The company’s 50-day moving average price is $136.19 and its two-hundred day moving average price is $133.03.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the firm posted $0.97 earnings per share. The company’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of research analyst reports. Citigroup boosted their target price on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. UBS Group reaffirmed a “neutral” rating and issued a $135.00 target price on shares of Illumina in a research note on Friday, February 6th. Piper Sandler dropped their target price on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Finally, Royal Bank Of Canada initiated coverage on shares of Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price for the company. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus target price of $138.38.

Institutional Investors Weigh In On Illumina

A number of hedge funds have recently modified their holdings of the business. Empowered Funds LLC lifted its stake in Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after buying an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Illumina during the second quarter worth $621,000. CW Advisors LLC bought a new stake in shares of Illumina during the second quarter worth $275,000. Marshall Wace LLP raised its holdings in shares of Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after acquiring an additional 19,618 shares during the period. Finally, Cresset Asset Management LLC raised its holdings in shares of Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after acquiring an additional 1,748 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, reflecting optimism about clinical sequencing momentum, consumables pricing, and the company’s pipeline. Article
• Positive Sentiment: Integrated DNA Technologies expanded its collaboration with Illumina, linking xGen FFPE and cfDNA workflows to DRAGEN and Connected Insights, which could deepen Illumina’s role in oncology research and support software adoption. Article
• Positive Sentiment: Recent commentary highlighted Illumina’s better execution, stronger NovaSeq X adoption, and higher full-year 2026 guidance, which has helped extend the stock’s rally. Article
• Neutral Sentiment: Illumina reported small insider sales, including a routine Rule 10b5-1 sale by the chief accounting officer, which is not unusual but adds to scrutiny around insider activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, which could weigh on sentiment despite no direct sign of operational weakness. SEC filing

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.